false
0001106644
0001106644
2025-12-22
2025-12-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): December
22, 2025
CHINA PHARMA HOLDINGS, INC.
(Exact name of Registrant as specified in charter)
| Nevada |
|
001-34471 |
|
73-1564807 |
| (State or other jurisdiction |
|
(Commission File No.) |
|
(IRS Employer |
| of Incorporation) |
|
|
|
Identification No.) |
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China 570216
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area
code: +86 898-6681-1730 (China)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425) |
| ☐ |
|
Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12) |
| ☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b)) |
| ☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock |
|
CPHI |
|
NYSE American |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 |
Entry into a Material Definitive Agreement. |
On December 22, 2025, Hainan Helpson Medical &
Biotechnology Co., Ltd (“Helpson”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “Company”),
entered into a Technology Transfer Agreement (the “Agreement”) with Juan Zhang (the “Transferor”).
The Transferor owns an invention patent of an Ipragliflozin tablets and Method for Its Preparation (the “Invention Patent”).
Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated
third party shall provide relevant technical services, which include but are not limited to product research and development, writing
of registration materials, registration application and other technical services.
The transfer price as contemplated by the Agreement
is $9.8 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the “Common Stock”),
at $1.40 per share.
| Item 3.02 |
Unregistered Sales of Equity Securities. |
The information contained in Item 1.01 of this Current
Report on Form 8-K in relation to the issuance of the Company’s securities mentioned above is incorporated herein by reference.
The Company is to issue an aggregate of 7,000,000 restricted shares of Common Stock in connection
with the technology transfer.
The Company’s securities mentioned above, if
and when issued, will not be registered under the Securities Act as amended (the “Securities Act”), or the securities
laws of any state, and are being offered and issued in reliance on the exemption from registration under the Securities Act afforded by
Regulation S promulgated thereunder for the issuance of the shares to the person who is a non-U.S. person as the securities are being
issued to the person through an offshore transaction which was negotiated and consummated outside the United States.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 23, 2025
| |
CHINA PHARMA HOLDINGS, INC. |
| |
|
| |
By: |
/s/ Zhilin Li |
| |
|
Name: Zhilin Li
Title: President and Chief Executive Officer |
